ライフサイエンスコーパス: lispro

1 and 4.4 events per patient-year with insulin lispro.

2 or glargine U100, both with prandial insulin lispro.

3 ec (n=349), both in combination with insulin lispro.

4 te of hypoglycemia was 12% less with insulin lispro (6.4 +/- 0.2 vs. 7.2 +/- 0.3 episodes/30 days, P

5 Insulin lispro, an insulin analog recently developed particularl

6 We compared insulin lispro and regular human insulin in the mealtime treatme

7 nd stressed therapeutic protein DPs, insulin lispro and rituximab.

8 ve types of insulin (human, bovine, porcine, Lispro, and Lantus) were used as model products in the s

9 tudies employed Lys(B28), Pro(B29)-insulin ("lispro") as a model prandial analog that is less thermod

10 ty of tirzepatide (pooled cohort) vs insulin lispro, both in addition to insulin glargine, in HbA1c c

11 ucose; for instance, the fast-acting insulin lispro contains two point mutations that suppress dimer

12 No evidence was noted that insulin lispro differs in immunogenicity from RHI in previously

13 kg with tirzepatide and 3.2 kg with insulin lispro (estimated treatment difference, -12.2 kg [95% CI

14 s regular, neutral protamine Hagedorn [NPH], lispro, glulisine, glargine, detemir, degludec, and aspa

15 ir and sofosbuvir tablets [Harvoni], insulin lispro [Humalog], and insulin aspart [Novolog]) and thei

16 In conclusion, insulin lispro improves postprandial control, reduces hypoglycem

17 largine, both combined with prandial insulin lispro, in patients with type 2 diabetes.

18 tiated, including human insulin (P28K29) and Lispro insulin (K28P29), which differ only by the interc

19 ed as prandial insulin (for example, insulin lispro, insulin aspart, or insulin glulisine) and basal

20 tors (glimepiride, insulin glargine, insulin lispro, liraglutide, pioglitazone, or sitagliptin).

21 Insulin lispro [Lys (B28), Pro (B29) human insulin] is a rapidly

22 [n = 236]) or prandial thrice-daily insulin lispro (n = 708).

23 For patients receiving insulin lispro, no significant changes occurred in antibody stat

24 irzepatide and 36% (256 of 708) with insulin lispro (odds ratio, 4.2 [95% CI, 3.2-5.5]).

25 glargine once daily and rapid-acting insulin lispro or aspart before meals (the basal-bolus group) du

26 ents were randomly assigned to begin insulin lispro or continue on RHI.

27 eas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insul

28 2.0 mmol/l in patients treated with insulin lispro (P < 0.001).

29 Dulaglutide in combination with lispro resulted in a significantly greater improvement i

30 oled cohort) was -2.1% vs -1.1% with insulin lispro, resulting in mean HbA1c levels of 6.7% vs 7.7% (

31 f insulin-specific antibodies (ISA), insulin lispro-specific antibodies (LSA), and cross-reactive ant

32 sotherm) is approximately twice as large for Lispro than for porcine insulin.

33 hypoglycemic episodes was less with insulin lispro than with regular human insulin therapy during th

34 ucose was significantly lower during insulin lispro therapy.

35 ting this allosteric switch, 3-iodo-Tyr(B26)-lispro thus illustrates how a nonstandard amino acid sub

36 t tyrosine adjoining the engineered sites in lispro (Tyr(B26)) by 3-iodo-Tyr (i) augments its thermod

37 All three fluorinated lispro variants reduce blood glucose in diabetic mice, e

38 we contrasted the immunogenicity of insulin lispro versus regular human insulin (RHI) in patients pr

39 Insulin lispro was injected immediately before the meal, and reg

40 Here we replace ProB29 of insulin lispro with 4R-fluoroproline, 4S-fluoroproline, and 4,4-